UBS Group’s China Biologic Products Holdings, Inc. CBPO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-102
| Closed | -$12K | – | 10414 |
|
|
2021
Q1 | $12K | Sell |
102
-3,154
| -97% | -$373K | ﹤0.01% | 7834 |
|
|
2020
Q4 | $385K | Buy |
3,256
+2,652
| +439% | +$308K | ﹤0.01% | 4809 |
|
|
2020
Q3 | $67K | Buy |
604
+42
| +7% | +$4.51K | ﹤0.01% | 5443 |
|
|
2020
Q2 | $57K | Sell |
562
-345
| -38% | -$36.9K | ﹤0.01% | 5757 |
|
|
2020
Q1 | $98K | Sell |
907
-7,710
| -89% | -$886K | ﹤0.01% | 5318 |
|
|
2019
Q4 | $1M | Buy |
8,617
+3,828
| +80% | +$443K | ﹤0.01% | 4213 |
|
|
2019
Q3 | $548K | Buy |
4,789
+3,796
| +382% | +$377K | ﹤0.01% | 4496 |
|
|
2019
Q2 | $94K | Buy |
993
+906
| +1,041% | +$85.3K | ﹤0.01% | 5419 |
|
|
2019
Q1 | $8K | Sell |
87
-929
| -91% | -$76K | ﹤0.01% | 6985 |
|
|
2018
Q4 | $78K | Buy |
1,016
+929
| +1,068% | +$68.4K | ﹤0.01% | 5755 |
|
|
2018
Q3 | $7K | Sell |
87
-15,983
| -99% | -$1.49M | ﹤0.01% | 7382 |
|
|
2018
Q2 | $1.6M | Sell |
16,070
-25,629
| -61% | -$2.21M | ﹤0.01% | 3365 |
|
|
2018
Q1 | $3.38M | Buy |
41,699
+19,054
| +84% | +$1.54M | ﹤0.01% | 2678 |
|
|
2017
Q4 | $1.78M | Buy |
22,645
+21,786
| +2,536% | +$1.81M | ﹤0.01% | 3283 |
|
|
2017
Q3 | $79K | Sell |
859
-12,093
| -93% | -$1.16M | ﹤0.01% | 5486 |
|
|
2017
Q2 | $1.47M | Buy |
12,952
+12,894
| +22,231% | +$1.44M | ﹤0.01% | 3288 |
|
|
2017
Q1 | $6K | Sell |
58
-50
| -46% | -$5.34K | ﹤0.01% | 6955 |
|
|
2016
Q4 | $11K | Sell |
108
-579
| -84% | -$67.7K | ﹤0.01% | 6894 |
|
|
2016
Q3 | $86K | Sell |
687
-127
| -16% | -$15K | ﹤0.01% | 5085 |
|
|
2016
Q2 | $86K | Sell |
814
-7,719
| -90% | -$896K | ﹤0.01% | 5140 |
|
|
2016
Q1 | $977K | Sell |
8,533
-100,739
| -92% | -$11.8M | ﹤0.01% | 3275 |
|
|
2015
Q4 | $15.6M | Buy |
109,272
+7,481
| +7% | +$864K | 0.01% | 1103 |
|
|
2015
Q3 | $9.14M | Sell |
101,791
-130
| -0.1% | -$13.7K | 0.01% | 1452 |
|
|
2015
Q2 | $11.7M | Buy |
101,921
+352
| +0.3% | +$37K | 0.01% | 1346 |
|
|
2015
Q1 | $9.7M | Buy |
101,569
+569
| +0.6% | +$42.6K | 0.01% | 1505 |
|
|
2014
Q4 | $6.79M | Buy |
+101,000
| New | +$6.26M | ﹤0.01% | 1829 |
|
UBS Group's CBPO Position: Q2 2021 in Review
UBS Group sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 102 shares — an estimated $12K sold.
UBS Group first reported a position in CBPO in Q4 2014 and held it in 26 quarters. The position peaked at $15.6M in Q4 2015. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.
- UBS Group reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
- UBS Group sold 102 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $12K.
- UBS Group first reported a position in China Biologic Products Holdings, Inc. in Q4 2014 and held it in 26 quarters.
- UBS Group's China Biologic Products Holdings, Inc. position peaked at $15.6M in Q4 2015.
- 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.
Based on UBS Group's 13F filing for Q2 2021, filed 13 Aug 2021.